N
ELVN icon

Nuveen’s Enliven Therapeutics ELVN Stock Holding History

Nuveen’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.15M Buy
105,883
+435
+0.4% +$12.1K ﹤0.01% 1960
2025
Q4 		$1.62M Sell
105,448
-2,796
-3% -$55.7K ﹤0.01% 2377
2025
Q3 		$2.22M Buy
108,244
+18,532
+21% +$374K ﹤0.01% 2265
2025
Q2 		$1.8M Sell
89,712
-14,387
-14% -$272K ﹤0.01% 2353
2025
Q1 		$2.05M Buy
104,099
+73
+0.1% +$1.57K ﹤0.01% 2329
2024
Q4 		$2.34M Buy
104,026
+317
+0.3% +$8.22K ﹤0.01% 2318
2024
Q3 		$2.65M Sell
103,709
-23,809
-19% -$551K ﹤0.01% 2283
2024
Q2 		$2.98M Buy
127,518
+44,523
+54% +$937K ﹤0.01% 2189
2024
Q1 		$1.46M Sell
82,995
-3,634
-4% -$55.8K ﹤0.01% 2535
2023
Q4 		$1.2M Sell
86,629
-338
-0.4% -$4.13K ﹤0.01% 2654
2023
Q3 		$1.19M Buy
86,967
+22,272
+34% +$375K ﹤0.01% 2509
2023
Q2 		$1.32M Buy
+64,695
New +$1.31M ﹤0.01% 2530
2021
Q2 		– Sell
-3,728
Closed -$126K – 3413
2021
Q1 		$126K Buy
+3,728
New +$189K ﹤0.01% 3270
2020
Q3 		– Sell
-1,989
Closed -$220K – 3309
2020
Q2 		$220K Buy
+1,989
New +$223K ﹤0.01% 3087

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nuveen's ELVN Position: Q1 2026 in Review

Nuveen increased its Enliven Therapeutics (ELVN) stake by 0.41% in Q1 2026, buying an estimated $12.1K and bringing the position to 105,883 shares worth $4.15M. The position accounts for ﹤0.01% of the portfolio, ranked #1960.

Nuveen first reported a position in ELVN in Q2 2020 and has held it in 14 quarters since. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Nuveen held 105,883 shares of Enliven Therapeutics worth $4.15M as of Q1 2026.
  • Nuveen bought 435 Enliven Therapeutics shares in Q1 2026, an estimated $12.1K.
  • Enliven Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #1960 holding.
  • Nuveen first reported a position in Enliven Therapeutics in Q2 2020 and has held it in 14 quarters since.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.